24/7 Market News Snapshot 06 January, 2025 – CytoMed Therapeutics Limited Ordinary Shares (NASDAQ:GDTC)

January 6, 2025

DENVER, Colo., 06 January, 2025 (247marketnews.com) – (NASDAQ:GDTC) are discussed in this article.
CytoMed Therapeutics Limited is experiencing significant momentum in the market, as evidenced by a remarkable increase in the trading value of its stock, GDTC, which surged by 90.61% to reach $6.576 during pre-market trading. This impressive growth follows an impressive trading volume of 2.60 million shares, showcasing heightened investor interest and confidence. Analysts are closely monitoring the bullish trend, indicative of growing optimism about the company’s future prospects and innovative advancements in the biotechnology sector.

Concurrently, CytoMed has embarked on a pivotal Business & Research Collaboration Agreement (BRCA) with SunAct Cancer Institute, a venture that aims to investigate innovative cancer treatment approaches. This collaboration will focus on the safety, tolerability, potency, and efficacy of CytoMed’s proprietary allogeneic gamma delta T cells in treating various types of cancer, particularly solid tumors. In a move to accelerate research efforts, both organizations will co-sponsor a Phase 2 investigator-initiated clinical trial, spearheaded by the esteemed Prof. Dr. Vijay Patil, a prominent figure in medical oncology and immunotherapy.

Dr. Patil expressed enthusiasm about this collaborative initiative, remarking on the importance of accessible and affordable cancer treatment options. CytoMed Chairman Peter Choo reinforced this sentiment, highlighting the company’s dedication to leveraging cutting-edge technology to enhance cancer treatment outcomes globally. The five-year BRCA underscores CytoMed’s commitment to providing crucial scientific and technical support while overseeing the manufacturing of the investigational product. This partnership embodies a strategic alignment of resources and expertise, setting the stage for transformative advancements in cancer therapy that could significantly elevate the quality of life for patients.

Related news for (GDTC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.